Abstract Acute Myeloid Leukemia (AML) patients with NPM1 mutations, known to cause
aberrant cytoplasmic re-localization, demonstrate a superior response to standard …

Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior
response to standard chemotherapy treatment. Our previous work has shown that these …

Abstract Background & Significance: Pre-B acute lymphoblastic leukemia (ALL) emerges in
virtually all cases from B cell precursors that are arrested at the pre-B cell receptor …

The Forkhead box protein M1 (FOXM1) is a transcription factor that plays a central role in the
regulation of cell cycle, proliferation, DNA repair, and apoptosis. FOXM1 is overexpressed in …

Abstract Objectives: Forkhead box M1 (FOXM1) is a transcription factor of the Forkhead
family that induces genes critical in executing the mitotic program. The FOXM1 regulatory …

Acute Myeloid Leukemia (AML) is a highly heterogeneous disease with 3-year patient
survival ranging from 30 to 80%, depending on molecular characteristics. Mutations in …

Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the
prognosis for patients with relapsed ALL remains poor. Here we identify FOXM1 as a …

NPM1 mutations are among the most common mutations in CN-AML (Cytogenetically
Normal-AML) and are known to enhance chemosensitivity in AML patients. Across multiple …

Forkhead box protein M1 (FOXM1) is a crucial regulator of cancer development and
chemoresistance. It is often overexpressed in acute myeloid leukemia (AML) and is …

Acute lymphoblastic leukemia (ALL) is the most common pediatric and adolescent
malignancy. Although current treatment provides five-year event-free survival, in up to 20 …